164 related articles for article (PubMed ID: 16781904)
21. Between-meal risedronate does not alter bone turnover in nursing home residents.
Agrawal S; Krueger DC; Engelke JA; Nest LJ; Krause PF; Drinka PJ; Binkley NC
J Am Geriatr Soc; 2006 May; 54(5):790-5. PubMed ID: 16696745
[TBL] [Abstract][Full Text] [Related]
22. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
Clemens JD; Herrick MV; Singer FR; Eyre DR
Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
[TBL] [Abstract][Full Text] [Related]
23. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Ikeda T; Maruyama K; Kaji H; Akagi M
Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
[TBL] [Abstract][Full Text] [Related]
24. Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids.
Benucci M; Saviola G; Baiardi P; Abdi-Ali L; Povino MR; Dolenti S; Campostrini L; Sacco S; Manfredi M; Rossini M
Clin Exp Rheumatol; 2009; 27(4):567-73. PubMed ID: 19772786
[TBL] [Abstract][Full Text] [Related]
25. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids.
Sawamura M; Komatsuda A; Togashi M; Wakui H; Takahashi N
Intern Med; 2017; 56(6):631-636. PubMed ID: 28321061
[TBL] [Abstract][Full Text] [Related]
26. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Kikuchi Y; Imakiire T; Yamada M; Saigusa T; Hyodo T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Suzuki S; Miura S
Nephrol Dial Transplant; 2007 Jun; 22(6):1593-600. PubMed ID: 17041001
[TBL] [Abstract][Full Text] [Related]
27. Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.
Hozuki T; Imai T; Tsuda E; Matsumura A; Yamamoto D; Toyoshima T; Suzuki S; Yamauchi R; Hayashi T; Hisahara S; Shimohama S
Intern Med; 2010; 49(5):371-6. PubMed ID: 20190467
[TBL] [Abstract][Full Text] [Related]
28. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
29. [The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
Altintaş F; Ozkut AT; Beyzadeoğlu T; Eren A; Güven M
Acta Orthop Traumatol Turc; 2007; 41(2):132-5. PubMed ID: 17483649
[TBL] [Abstract][Full Text] [Related]
30. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
31. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
Iwasaki T; Nonoda Y; Ishii M
Curr Med Res Opin; 2012 May; 28(5):737-47. PubMed ID: 22126423
[TBL] [Abstract][Full Text] [Related]
33. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
Rosen HN; Dresner-Pollak R; Moses AC; Rosenblatt M; Zeind AJ; Clemens JD; Greenspan SL
Calcif Tissue Int; 1994 Jan; 54(1):26-9. PubMed ID: 8118749
[TBL] [Abstract][Full Text] [Related]
34. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
35. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
[TBL] [Abstract][Full Text] [Related]
36. The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment.
Callaci JJ; Juknelis D; Patwardhan A; Sartori M; Frost N; Wezeman FH
Alcohol Clin Exp Res; 2004 Jan; 28(1):182-91. PubMed ID: 14745317
[TBL] [Abstract][Full Text] [Related]
37. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
[TBL] [Abstract][Full Text] [Related]
38. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients.
Maeno Y; Inaba M; Okuno S; Yamakawa T; Ishimura E; Nishizawa Y
Clin Chem; 2005 Dec; 51(12):2312-7. PubMed ID: 16223890
[TBL] [Abstract][Full Text] [Related]
39. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
40. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
